Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.51 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.51 |
| ▸ | PI4KA | P42356 | 2/20 | 0.45 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.45 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.45 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | DRD3 | P35462 | 1/20 | 0.45 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.45 |
| ▸ | CDK2 | P24941 | 9/20 | 0.43 |
| ▸ | CDK1 | P06493 | 8/20 | 0.43 |
| ▸ | CCNB1 | P14635 | 8/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 8/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | POLA1 | P09884 | 1/20 | 0.39 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29384383 | 0.86 | PDPK1 (0.53) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL25860 | 0.86 | PDPK1 (0.53) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL2402087 | 0.85 | PDPK1 (0.51) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL28144662 | 0.80 | PDPK1 (0.46) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL1924592 | 0.79 | PDPK1 (0.59) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL29592683 | 0.79 | PDPK1 (0.59) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL30150749 | 0.79 | PDPK1 (0.51) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL19840 | 0.79 | PDPK1 (0.51) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL11222102 | 0.79 | PDPK1 (0.63) | PDPK1GDAPI4KAPI4K2BPI4K2A | |
| SCHEMBL2909569 | 0.78 | PDPK1 (0.50) | PDPK1GDAPI4KAPI4K2BPI4K2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260022379-A1 | Optimized RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of Use | ARROWHEAD PHARMACEUTICALS INC (US) | 2026-01-22 | — | — | US | disclosed |
| US-12486502-B2 | RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use | Arrowhead Pharmaceuticals, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| EP-2329830-A2 | Antisense inhibition of PTP1B expression | ISIS Pharmaceuticals, Inc. (US) | 2011-06-08 | — | — | EP | disclosed |
| US-20050026182-A1 | Human CDNAS and proteins and uses thereof | SERONO GENETICS INSTITUTE S.A. (FR) | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022379-A1 | Optimized RNAi Agents for Inhibiting Expression of Coronavirus (CoV) Viral Genomes, Compositions Thereof, and Methods of Use | SARS1, RBM26, METTL16 | PDPK1 4668/4885GDA 3397/4885PI4KA 4677/4885 |
| US-12486502-B2 | RNAi agents for inhibiting expression of receptor for advanced glycation end-products, compositions thereof, and methods of use | AGER, ASGR1, TLR3 | PDPK1 3439/4885GDA 477/4885PI4KA 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.